Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312972 · ClinicalTrials.gov registry record · NA
Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
A NA study of Locally Recurrent Prostate Cancer, sponsored by Loyola University.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03312972 is a NA study of Locally Recurrent Prostate Cancer that is active but no longer recruiting, run by Loyola University. The registered enrollment target is 50 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03312972, a NA study of Locally Recurrent Prostate Cancer, is active but no longer recruiting, sponsored by Loyola University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy. The study will examine the safety and efficacy of the treatment. The type of radiation that participants in this research will receive is targeted directly at the areas of the prostate where recurrent disease is evident, while avoiding treatment of the normal appearing prostate. This involves the placement of a radioactive material in the affected area of the prostate temporarily, where it remains for a short period of time, and then is subsequently removed using a minimally invasive technique called HDR Brachytherapy.
Conditions Studied
Interventions
- RADIATION HDR Brachytherapy
Study Locations (2)
Illinois
- Loyola University Medical Center - Maywood
Virginia
- University of Virginia School of Medicine - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03312972
The ClinicalTrials.gov registry entry for NCT03312972 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Recurrent Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which HDR Brachytherapy is the first listed.
NCT03312972 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Virginia.
Frequently Asked Questions
What is clinical trial NCT03312972 about?
NCT03312972 is a clinical study titled "Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy". This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy. The study will examine the safety and efficacy of the treatment. The typ...
What is the current status of trial NCT03312972?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2017-08-28. Estimated completion is 2026-07-31.
What conditions does trial NCT03312972 study?
This clinical trial studies the following conditions: Locally Recurrent Prostate Cancer.
What interventions are being tested in trial NCT03312972?
The interventions under investigation include: HDR Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT03312972?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03312972 being conducted?
This trial has 2 study locations across Illinois, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.